Short answer
MAXCYTE, INC. (MXCT) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5M (down 18.0% year over year) with net income of −$12M.
Q3 2025 key financials · XBRL
- Revenue
- $5M
- −18.0% YoY · −21.0% QoQ
- Net income
- −$12M
- −7.4% YoY · −0.5% QoQ
- Operating margin
- -307.4%
- Gross margin
- 113.7%
- EPS (diluted)
- −$0.12
- −9.1% YoY · −9.1% QoQ
Source: XBRL data from the MAXCYTE, INC. (MXCT) Q3 2025 10-Q on SEC EDGAR. USD.
MAXCYTE, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- CFO transition effective Retention Date, creating near-term finance leadership continuity risk
- CFO retention package: $150,000 one-time payment plus $10,000 monthly consulting fee after May 31, 2026
- Director Rekha Hemrajani’s previously omitted Rule 10b5-1 Plan covers 130,684 securities through June 1, 2026
- No material change in planned IPO-proceeds use since the final prospectus
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MAXCYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.